The Vietnam pharmaceuticals market size is expected to be valued at US$ 7.2 billion in 2026 and projected to reach US$ 11.5 billion, growing at a CAGR of 6.8% between 2026 and 2033. It is one of the fast-growing markets in South Asia, supported by economic development, expanding healthcare coverage, and increasing demand for modern medical treatments. Rising life expectancy, urbanization, and a growing burden of chronic diseases such as cancer, diabetes, and cardiovascular disorders continue to drive pharmaceutical consumption across the country.

Government initiatives aimed at improving healthcare accessibility and strengthening domestic pharmaceutical manufacturing have further supported market expansion. The sector comprises a mix of multinational and local companies supplying branded medicines, generics, biologics, and traditional medicines through hospital and retail channels. Increasing healthcare expenditure, broader insurance coverage, and ongoing investments in healthcare infrastructure are expected to enhance medicine access and create favorable conditions for sustained pharmaceutical market growth in Vietnam.

Drivers - Escalating Chronic Disease Burden and Aging Demographics

Vietnam is undergoing a rapid epidemiological transition, with non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, cancer, and chronic respiratory disorders accounting for  77% of total mortality, according to the World Health Organization (WHO). The International Diabetes Federation (IDF) estimated that nearly 7 million Vietnamese adults were living with diabetes in 2021, and this number is expected to increase due to urbanization, lifestyle changes, and dietary shifts. The growing prevalence of chronic diseases is generating sustained demand for pharmaceuticals across cardiovascular, oncology, diabetes, and respiratory therapeutic categories, making healthcare treatment and disease management a key market growth driver.

At the same time, Vietnam is becoming one of the fastest-aging countries in Southeast Asia. According to the United Nations Population Fund (UNFPA), individuals aged 60 years and above are projected to represent 20% of the country's population by 2038. An aging population typically requires more frequent medical care and long-term medication use, particularly for chronic illnesses. This demographic trend is expected to increase pharmaceutical consumption significantly and support continued market expansion across both specialty and primary care treatment segments.

Restraints- High Dependence on Imported Active Pharmaceutical Ingredients (APIs)

Despite the growth of Vietnam's pharmaceutical manufacturing sector, the industry remains heavily dependent on imported active pharmaceutical ingredients (APIs). According to the Vietnam Pharmaceutical Companies Association (VNPCA),  80–90% of API requirements are imported, primarily from China and India. This reliance exposes domestic manufacturers to external risks, including supply-chain disruptions, geopolitical uncertainties, and fluctuations in foreign exchange rates. Any interruption in API supply can directly affect production continuity and medicine availability within the country.

Additionally, increasing API procurement costs place significant financial pressure on local pharmaceutical companies. Higher import expenses reduce manufacturing margins and limit the competitiveness of domestically produced medicines compared with imported finished pharmaceutical products. The vulnerabilities associated with API dependence became particularly evident during the COVID-19 pandemic, when global supply-chain disruptions affected raw material availability. Unless Vietnam strengthens domestic API production capabilities, this structural dependence is likely to remain a key challenge for the industry's long-term growth and resilience.

Opportunities- E-Commerce and Digital Pharmacy Channel Development

Vietnam's rapidly expanding digital economy presents a significant growth opportunity for the pharmaceutical industry. As per validated online studies Vietnam continues to rank among Southeast Asia's fastest-growing digital markets, driven by increasing internet usage, smartphone adoption, and digital consumer engagement. Recognizing this trend, the Vietnam Ministry of Health issued guidelines in 2023 permitting the online sale of non-prescription medicines through licensed digital pharmacy platforms, creating a formally regulated framework for pharmaceutical e-commerce. This regulatory development is enabling pharmaceutical manufacturers, retailers, and healthcare providers to expand their reach beyond traditional distribution channels and improve access to healthcare products across the country.

The opportunity is further strengthened by Vietnam's high digital connectivity, with internet penetration reaching  79% of the population, according to Statista. Rapid smartphone adoption in Tier-2 and Tier-3 cities is expanding the addressable customer base for online healthcare services and pharmacy platforms. Digital channels offer pharmaceutical companies a scalable and cost-effective route to underserved consumers while reducing reliance on physical retail expansion. Companies investing in compliant digital pharmacy partnerships, telehealth integration, and targeted digital health marketing strategies are expected to gain a competitive advantage and capture a substantial share of Vietnam's emerging online pharmaceutical market.

Drug Classification Insights

Branded/Innovator Drugs are expected to account for  56% of the Vietnam pharmaceuticals market in 2026, maintaining their leadership position across both hospital and retail channels. Their dominance is supported by physician prescribing preferences, established clinical trust, and favorable reimbursement under Vietnam's National Health Insurance (NHI) system. Multinational pharmaceutical companies continue to hold strong positions in specialty and high-value therapeutic areas, particularly within public hospitals and tertiary care facilities.

Although government initiatives encourage the use of locally manufactured generics, branded innovator products continue to benefit from strong brand recognition and patient confidence regarding quality and efficacy. Limited bioequivalence testing capacity and cautious generic substitution practices further support demand for originator medicines. As healthcare spending increases and access to advanced therapies expands, branded products are expected to retain a substantial share of the market despite growing competition from domestic manufacturers and biosimilar alternatives.

Therapeutic Area Insights

The infectious diseases & vaccines is projected to remain the largest therapeutic category in Vietnam's pharmaceutical market, accounting for 28% of total revenues in 2026. The country continues to face a significant burden of communicable diseases, including tuberculosis, hepatitis B, dengue fever, and seasonal respiratory infections. According to public health estimates, Vietnam has more than 8 million chronic hepatitis B carriers, creating sustained demand for antiviral medications and disease management therapies.

Strong government support for immunization programs further reinforces segment growth. Vietnam's National Expanded Program on Immunization (EPI) maintains vaccination coverage rates exceeding 95% for key childhood vaccines, resulting in substantial annual vaccine procurement. In addition, increasing awareness of preventive healthcare and the introduction of newer vaccines are supporting market expansion. Continued investments in disease surveillance, public health infrastructure, and vaccination initiatives are expected to sustain the segment's leading position over the forecast period.

Distribution Channel Analysis

Retail and Community Pharmacies are expected to dominate Vietnam's pharmaceutical distribution landscape, accounting for 42% of market revenues in 2026. The country has more than 65,000 registered pharmacies, creating one of the most extensive pharmaceutical retail networks in Southeast Asia. These outlets provide convenient access to prescription medicines, over-the-counter products, and health supplements, making them the primary point of purchase for a large portion of the population.

The widespread practice of self-medication and relatively high out-of-pocket healthcare expenditure continue to support strong pharmacy traffic across urban and rural areas. Meanwhile, direct tenders and public-sector procurement remain important channels due to large-scale hospital purchasing under the National Health Insurance system. E-commerce and online pharmacies are anticipated to be the fastest-growing distribution segment, supported by regulatory approval, rising internet penetration, expanding smartphone usage, and growing consumer acceptance of digital healthcare services.

South Vietnam Pharmaceuticals Market Trends and Insights

South Vietnam is expected to remain the largest regional pharmaceutical market in Vietnam, accounting for 46% of national pharmaceutical revenues in 2026. Led by Ho Chi Minh City, the region benefits from a highly developed healthcare ecosystem that includes major private hospitals, specialty treatment centers, research institutions, and a strong presence of multinational pharmaceutical companies. Higher disposable incomes, greater healthcare awareness, and widespread access to advanced medical services support robust demand for prescription medicines, specialty drugs, and innovative therapies.

The region also serves as Vietnam's primary pharmaceutical commercial hub, hosting a large share of licensed importers, distributors, and regional headquarters of global pharmaceutical manufacturers. New product launches and advanced biologic therapies are often introduced in South Vietnam before expanding nationwide. Continued investments in healthcare infrastructure, private healthcare services, and pharmaceutical distribution networks are expected to reinforce the region's leadership position throughout the forecast period.

Central Vietnam Pharmaceuticals Market Trends and Insights

Central Vietnam is projected to be the fastest-growing pharmaceutical region supported by rapid urbanization, rising household incomes, and expanding healthcare access. The region, centered around Da Nang and Hue, is expected to account for 19% of national pharmaceutical revenues in 2026. Government investments in hospitals, medical facilities, and healthcare modernization programs are improving treatment accessibility and driving demand for pharmaceutical products across both urban and semi-urban populations.

In addition, private healthcare providers and pharmaceutical distributors are increasingly expanding operations into Central Vietnam to capture growth opportunities beyond the mature markets of Ho Chi Minh City and Hanoi. Rising awareness of preventive healthcare, increasing chronic disease prevalence, and improving healthcare infrastructure are creating favorable conditions for pharmaceutical market expansion. These factors are expected to accelerate medicine consumption and attract greater investment from both domestic manufacturers and multinational pharmaceutical companies over the coming years.

The Vietnam pharmaceuticals market is moderately fragmented, with multinational companies including Sanofi, GSK, Pfizer, and Roche collectively commanding the premium and specialty segments, while domestic champions including DHG Pharma (Hau Giang Pharmaceutical JSC) and Traphaco lead in generic and traditional medicine categories. Multinationals compete primarily through tender qualification, physician relationship management, and portfolio breadth, while domestic firms leverage price competitiveness and government preference policies under the Group 1 and Group 2 domestic sourcing preference framework. Emerging strategic themes include local manufacturing partnerships, e-pharmacy distribution agreements, and biosimilar portfolio development.

Key Developments

• In March 2026, Vietnam initiated clinical trials for a novel antiviral drug aimed at treating dengue fever, marking a significant step toward addressing a disease for which no approved targeted treatment currently exists globally.
• In March 2026, Meiji Seika Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announced the launch of EPADEL S900 (Ethyl Icosapentate) in Vietnam through their local partner, Thien Thao Pharmaceutical Joint Stock Company.
• In May 2025, Imexpharm Corporation announced plans to invest VND 1.5 trillion (US$58 million) to build the Cat Khanh Pharmaceutical Plant in Dong Thap Province, southern Vietnam. The facility is expected to begin construction in Q4 2025 and, once fully operational between 2028 and 2030, will have an annual production capacity of 1.4 billion pharmaceutical products.